Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FMC Biopolymer was a leading global supplier of naturally derived polymers and specialty substances for the pharmaceutical, food, and personal care industries. The company specialized in high-quality excipients, most notably microcrystalline cellulose under the Avicel brand, as well as alginates and carrageenan. These products are critical components in drug formulation, serving as binders, disintegrants, and stabilizers for solid oral dosages and other delivery systems. In 2017, the business was acquired by DuPont as part of a strategic asset swap with FMC Corporation. Following the 2021 merger between IFF and DuPont's Nutrition & Biosciences division, these assets are now part of IFF Pharma Solutions. The company's legacy continues to provide essential technical expertise and material science solutions to the global healthcare market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on FMC Biopolymer.